Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Shutterstock/NeydtStock

Trinity scientists believe they have made a breakthrough in treating asthma and eczema

Scientists believe their breakthrough could help create new drugs to treat allergic conditions.

SCIENTISTS FROM TRINITY College have said they have made a “significant breakthrough” in understanding the immune cells which play a vital role in diseases such as asthma and eczema.

Researchers from the Dublin university said they identified what they described as a ‘checkpoint’ “manned by these immune cells that, if barred, can halt the development of the lung inflammation associated with allergies”.

The work has just been published in the peer-reviewed medical journal The Journal of Experimental Medicine.

The team of scientists was led by Padraic Fallon of the School of Medicine in the Trinity Biomedical Sciences Institute.

He said: “The discovery now provides a potential new target for drug developers on which to hone in. In theory, a drug that successfully regulates this newly pinpointed checkpoint would better control overly aggressive allergic responses.”

Fallon added that this identification of an early stage cellular checkpoint has “important implications for the development of new therapeutic approaches” for asthma and other allergic diseases.

First author of the paper, Dr Christian Schwartz, said she believes that the more scientists learn about these cellular networks, the more possibilities they will be able to “create for intervention”.

Read: ‘That son-in-law, I hate him’: Thomas Martens told co-worker he hated Jason Corbett, court hears >

Close
37 Comments
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.